[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100618173":3},{"organization":4,"armGroups":7,"interventions":40,"overallOfficials":44,"centralContacts":10,"locations":49,"responsibleParty":85,"collaborators":10,"id":89,"slug":90,"hasResults":91,"nctId":92,"briefTitle":93,"officialTitle":93,"acronym":94,"eligibilityCriteria":95,"healthyVolunteers":96,"sex":97,"minAge":98,"maxAge":10,"enrollmentInfo":99,"targetDuration":10,"studyType":102,"phases":10,"briefSummary":103,"conditions":104,"keywords":10,"overallStatus":51,"whyStopped":10,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":123},{"fullName":5,"class":6},"KU Leuven","OTHER",[8,13,17,21,25,28,31,34,37],{"label":9,"type":10,"description":10,"interventionNames":11},"Healthy controls",null,[12],"Other: Blood sample collection",{"label":14,"type":10,"description":15,"interventionNames":16},"Patients with type I allergy","Including medication allergy, venom allergy, food allergy, allergic rhinitis",[12],{"label":18,"type":10,"description":19,"interventionNames":20},"Patients with chronic spontaneous urticaria","With or without omalizumab",[12],{"label":22,"type":10,"description":23,"interventionNames":24},"Patients with a recent history of anaphylaxis","In whom serial sampling can be performed",[12],{"label":26,"type":10,"description":10,"interventionNames":27},"Patients undergoing desensitization for venom allergy",[12],{"label":29,"type":10,"description":10,"interventionNames":30},"Patients undergoing desensitization for medication allergy",[12],{"label":32,"type":10,"description":10,"interventionNames":33},"Patients with mastocytosis",[12],{"label":35,"type":10,"description":10,"interventionNames":36},"Patients with hereditary alpha tryptasemia",[12],{"label":38,"type":10,"description":10,"interventionNames":39},"Patients with X-linked agammaglobulinemia (XLA)",[12],[41],{"type":6,"name":42,"description":42,"armGroupLabels":43,"otherNames":10},"Blood sample collection",[9,29,26,38,22,18,35,32,14],[45],{"name":46,"affiliation":47,"role":48},"Rik Schrijvers, MD, PhD","UZ\u002FKU Leuven","PRINCIPAL_INVESTIGATOR",[50],{"facility":47,"status":51,"city":52,"state":53,"zip":54,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"RECRUITING","Leuven","Vlaams-Brabant","3000","Belgium","BE",{"type":58,"coordinates":59},"Point",[60,61],4.70093,50.87959,{"lat":61,"lon":60},[64,68,72,73,76,78,80,81,83],{"name":46,"role":65,"phone":66,"phoneExt":10,"email":67},"CONTACT","016342985","rik.schrijvers@uzleuven.be",{"name":69,"role":65,"phone":70,"phoneExt":10,"email":71},"Dries Wets, MD","016338198","dries.wets@kuleuven.be",{"name":46,"role":48,"phone":10,"phoneExt":10,"email":10},{"name":74,"role":75,"phone":10,"phoneExt":10,"email":10},"Paul Proost, PhD","SUB_INVESTIGATOR",{"name":77,"role":75,"phone":10,"phoneExt":10,"email":10},"Frans Glynis, PharmD, PhD,",{"name":79,"role":75,"phone":10,"phoneExt":10,"email":10},"Christine Breynaert, MD, PhD",{"name":69,"role":75,"phone":10,"phoneExt":10,"email":10},{"name":82,"role":75,"phone":10,"phoneExt":10,"email":10},"Rafaela Vaz Pereira, PhD",{"name":84,"role":75,"phone":10,"phoneExt":10,"email":10},"Toon Ieven, MD, PhD",{"type":48,"investigatorFullName":86,"investigatorTitle":87,"investigatorAffiliation":88,"oldNameTitle":10,"oldOrganization":10},"Rik Schrijvers","Prof. Dr. Rik Schrijvers","Universitaire Ziekenhuizen KU Leuven","100618173","analysis-of-the-role-of-ige-proteoforms-in-health-and-disease-100618173",false,"NCT07328178","Analysis of the Role of IgE Proteoforms in Health and Disease","IgE-PhD","Inclusion Criteria:\n\n* CSU and type I allergic diseases (including anaphylaxis and desensitization), atopic dermatitis, mastocytosis, XLA and HaT (informed consent, age: any available adult subject, gender: any available subject, clinical phenotype and specific information about the allergy (e.g. severity, medication, medical history, laboratory testing)\n* Healthy controls (informed consent, age matched to the allergic patients, gender matched to the allergic patients, patient-reported symptoms related to allergy to aeroallergens, food, drugs, hymenoptera venom, CSU)\n\nExclusion Criteria:\n\n* Absence of informed consent\n* Age \\\u003C 18 years old",true,"ALL","18 Years",{"count":100,"type":101},200,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to evaluate the role of IgE proteoforms in healthy volunteers and in patients with type I allergy, patients with chronic spontaneous urticaria, patients with a recent history of anaphylaxis, patients with mastocytosis, patients with hereditary alpha tryptasemia, patients with X-linked agammaglobulinemia (XLA), and patients undergoing desensitization for venom or medication allergy.",[105,106,107,108,109,110,111,112,113],"Anaphylaxis","Mastocytosis","X-linked Agammaglobulinaemia","Venom Allergy","Chronic Spontaneous Urticaria (CSU)","Type I Allergy","Medication Allergy","Healthy Control","Hereditary Alpha-Tryptasemia","2025-12-26",{"date":116,"type":117},"2026-01-09","ACTUAL",{"date":119,"type":117},"2025-01-01",{"date":121,"type":101},"2029-01-01",{"name":5,"class":6},1]